← Search & browse all drugs
CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS, OTHER COMBINATIONS › Beta blocking agents and calcium channel blockers
atenolol and nifedipine
C07FB03
Forms & Strengths
- Fixed-dose combination capsule/tablet containing Atenolol 50 mg / Nifedipine 20 mg
- Fixed-dose combination capsule/tablet containing Atenolol 50 mg / Nifedipine 10 mg
Adult Dosing
- Hypertension: 1 capsule/tablet once daily, adjusted based on individual component titration
- Maximum daily dose: 100 mg atenolol / 40 mg nifedipine
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Management of essential hypertension
- Angina pectoris
Mechanism of Action
- Atenolol is a cardioselective beta-1 adrenergic receptor blocker, decreasing heart rate, cardiac contractility, and blood pressure
- Nifedipine is a dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral arterial vasodilation
Contraindications
- Known hypersensitivity to atenolol, nifedipine, or other dihydropyridines/beta-blockers
- Sinus bradycardia, cardiogenic shock, and overt cardiac failure
- Second- or third-degree atrioventricular block
- Severe aortic stenosis (for the nifedipine component)
Adverse Reactions
- Peripheral edema, flushing, and headache secondary to nifedipine-induced vasodilation
- Bradycardia, fatigue, dizziness, and cold extremities secondary to atenolol
- Hypotension and gastrointestinal disturbances (nausea, constipation)
Drug Interactions
- Additive blood pressure-lowering effects with other antihypertensive agents, diuretics, and nitrates
- Concomitant use with digitalis glycosides, verapamil, or diltiazem may increase risk of bradycardia and AV conduction disturbances
- Nifedipine is metabolized by CYP3A4; strong inducers or inhibitors of CYP3A4 may alter nifedipine plasma concentrations
Curated Content: Needs Vetting Before Put to Clinical Use